Growth-hormone dependence among human breast cancers

Published on Wednesday, 24 April 2013


In-vitro dependence on growth hormone has been shown in the same 40% of twenty-six human breast cancers which also showed prolactin dependence.

The human growth hormone used had less than 0·1% prolactin.

This in-vitro finding best explains why, even when plasma-prolactin is much reduced by drugs, prolactin-dependent breast cancer often does not show regression and why hypophysectomy remains the first treatment of choice for such selected cancers.



About this publication.


See also:

- Somatostatin in oncology, the overlooked evidences;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.